Current Treatment Options in Oncology最新文献_第8页

Treatment of Relapsed Acute Lymphocytic Leukemia in Adult Patients. 治疗成人急性淋巴细胞白血病复发。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-08-01 Epub Date: 2024-06-25 DOI: 10.1007/s11864-024-01213-4

John C Molina, Hetty E Carraway

{"title":"Treatment of Relapsed Acute Lymphocytic Leukemia in Adult Patients.","authors":"John C Molina, Hetty E Carraway","doi":"10.1007/s11864-024-01213-4","DOIUrl":"10.1007/s11864-024-01213-4","url":null,"abstract":"Opinion statement: For adult patients diagnosed with relapsed B cell-ALL (B-ALL), there have been significant improvements in available treatment options following the FDA approval of novel cellular and immunotherapy approaches - blinatumomab, chimeric antigen receptor (CAR) T therapy, and inotuzumab. For the last several years, research has focused on gaining a better understanding of the effects of specific disease and patient characteristics on long-term outcomes with each of the FDA-approved agents. In combination with the better prevention and management of unique, treatment-specific toxicities, providers can now select the best available treatment option for each individual patient diagnosed with relapsed, adult B-ALL needing therapy. This has allowed more patients to proceed to consolidative hematopoietic stem cell transplant (HSCT), and long-term data has even brought into question the need for HSCT for long-term durable remission for all patients. However, with the adoption of blinatumomab, CAR T therapy, and inotuzumab in front-line treatment regimens, it remains unclear what effects this will have on patients with relapsed B-ALL following exposure to these novel cellular and immunotherapy therapies. Unlike B-ALL, similar advances have unfortunately not yet been realized in T cell-ALL (T-ALL). Currently, new therapeutic approaches are underway to utilize similar targeting strategies that have been successful in B-ALL - monoclonal antibodies, bispecific T-cell engagers (BiTE), and CAR T therapy. Like B-ALL, the only existing approved therapy for relapsed T-ALL, nelarabine, is now used in the upfront treatment setting potentially limiting its utility in relapsed disease. Over the next several years, the hope is for patients diagnosed with T-ALL to experience the drastic improvement in outcomes as has been seen for patients diagnosed with B-ALL over the last decade.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"993-1010"},"PeriodicalIF":3.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11329612/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141447433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiovascular Considerations in Patients Undergoing Hematopoietic Cell Transplantation. 造血细胞移植患者的心血管注意事项

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-08-01 Epub Date: 2024-07-25 DOI: 10.1007/s11864-024-01240-1

Jasmin Hundal, Thomas Curley, Betty K Hamilton

{"title":"Cardiovascular Considerations in Patients Undergoing Hematopoietic Cell Transplantation.","authors":"Jasmin Hundal, Thomas Curley, Betty K Hamilton","doi":"10.1007/s11864-024-01240-1","DOIUrl":"10.1007/s11864-024-01240-1","url":null,"abstract":"Opinion statement: Cardiac dysfunction is a serious adverse effect of cancer therapies that can interfere with quality of life and impact long-term survival in patients with cancer. Hematopoietic cell transplantation is a potentially curative therapy for many advanced hematologic malignancies and bone marrow failure syndromes, however is associated with several short- and long-term adverse effects, including importantly, cardiovascular toxicities. The goal of this review article is to describe the cardiovascular events that may develop before, during, and after hematopoietic cell transplantation, review risk factors for short- and long-term cardiovascular toxicities, discuss approaches to cardiovascular risk stratification and evaluation, and highlight the research gaps in the consideration of cardiovascular disease in patients undergoing hematopoietic cell transplantation. Further understanding of cardiovascular events and the factors associated with cardiovascular disease will hopefully lead to novel interventions in managing and mitigating the significant long-term burden of late cardiovascular effects in transplant survivors.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"1027-1037"},"PeriodicalIF":3.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11329532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141762365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Opportunities and Challenges in Soft Tissue Sarcoma Risk Stratification in the Era of Personalised Medicine. 个性化医疗时代软组织肉瘤风险分层的机遇与挑战。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-08-01 Epub Date: 2024-07-30 DOI: 10.1007/s11864-024-01244-x

Avirup Chowdhury, Khin Thway, Sandro Pasquali, Dario Callegaro, Alessandro Gronchi, Robin L Jones, Paul H Huang

{"title":"Opportunities and Challenges in Soft Tissue Sarcoma Risk Stratification in the Era of Personalised Medicine.","authors":"Avirup Chowdhury, Khin Thway, Sandro Pasquali, Dario Callegaro, Alessandro Gronchi, Robin L Jones, Paul H Huang","doi":"10.1007/s11864-024-01244-x","DOIUrl":"10.1007/s11864-024-01244-x","url":null,"abstract":"Opinion statement: Soft tissue sarcomas (STS) are a rare and heterogeneous group of cancers. Treatment options have changed little in the past thirty years, and the role of neoadjuvant chemotherapy is controversial. Accurate risk stratification is crucial in STS in order to facilitate clinical discussions around peri-operative treatment. Current risk stratification tools used in clinic, such as Sarculator, use clinicopathological characteristics and may be specific to anatomical site or to histology. More recently, risk stratification tools have been developed using molecular or immunological data. Combining Sarculator with other risk stratification tools may identify novel patient groups with differential clinical outcomes. There are several considerations when translating risk stratification tools into widespread clinical use, including establishing clinical utility, health economic value, being applicable to existing clinical pathways, having strong real-world performance, and being supported by investment into infrastructure. Future work may include incorporation of novel modalities and data integration techniques.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"1124-1135"},"PeriodicalIF":3.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141856980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment Options for Brain Metastases. 脑转移瘤的治疗方案。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-08-01 Epub Date: 2024-07-22 DOI: 10.1007/s11864-024-01195-3

Ariel Choi, John Hunting, Claire Lanier, Emily Douglas, Pierre Triozzi, Jimmy Ruiz, Marc Benayoun, Jaclyn White, Michael Chan

引用次数: 0

Recent Advances in Immunotherapy for Advanced Biliary Tract Cancer 晚期胆道癌免疫疗法的最新进展

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2024-07-27 DOI: 10.1007/s11864-024-01243-y

Shiwei Yue, Yunpu Zhang, Wei Zhang

{"title":"Recent Advances in Immunotherapy for Advanced Biliary Tract Cancer","authors":"Shiwei Yue, Yunpu Zhang, Wei Zhang","doi":"10.1007/s11864-024-01243-y","DOIUrl":"https://doi.org/10.1007/s11864-024-01243-y","url":null,"abstract":"Biliary tract cancer (BTC) is a heterogeneous group of aggressive malignancies that arise from the epithelium of the biliary tract. Most patients present with locally advanced or metastatic disease at the time of diagnosis. For patients with unresectable BTC, the survival advantage provided by systemic chemotherapy was limited. Over the last decade, immunotherapy has significantly improved the therapeutic landscape of solid tumors. There is an increasing number of studies evaluating the application of immunotherapy in BTC, including immune checkpoint inhibitors (ICIs), cancer vaccines and adoptive cell therapy. The limited response to ICIs monotherapy in unselected patients prompted investigators to explore different combination therapy strategies. Early clinical trials of therapeutic cancer vaccination and adoptive cell therapy have shown encouraging clinical results. However, there still has been a long way to go via validation of therapeutic efficacy and exploration of strategies to increase the efficacy. Identifying biomarkers that predict the response to immunotherapy will allow a more accurate selection of candidates. This review will provide an up-to-date overview of the current clinical data on the role of immunotherapy, summarize the promising biomarkers predictive of the response to ICIs and discuss the perspective for future research direction of immunotherapy in advanced BTC.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"61 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141776332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancements in Melanoma Therapies: From Surgery to Immunotherapy 黑色素瘤疗法的进展：从手术到免疫疗法

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2024-07-27 DOI: 10.1007/s11864-024-01239-8

Neda Shajari, Behzad Baradaran, Mohammad Reza Tohidkia, Hadi Nasiri, Maryam Sepehri, Sepideh Setayesh, Leili Aghebati‐Maleki

{"title":"Advancements in Melanoma Therapies: From Surgery to Immunotherapy","authors":"Neda Shajari, Behzad Baradaran, Mohammad Reza Tohidkia, Hadi Nasiri, Maryam Sepehri, Sepideh Setayesh, Leili Aghebati‐Maleki","doi":"10.1007/s11864-024-01239-8","DOIUrl":"https://doi.org/10.1007/s11864-024-01239-8","url":null,"abstract":"Melanoma is defined as the most aggressive and deadly form of skin cancer. The treatment of melanoma depends on the disease stage, tumor location, and extent of its spread from its point of origin. Melanoma treatment has made significant advances, notably in the context of targeted and immunotherapies. Surgical resection is the main therapeutic option for earlystage melanoma, and it provides favourable outcomes. With disease metastasis, systemic treatments such as immunotherapy and targeted therapy become increasingly important. The identification of mutations that lead to melanoma has influenced treatment strategies. Targeted therapies focusing on these mutations offer improved response rates and fewer toxicities than conventional chemotherapy. Furthermore, developing immunotherapies, including checkpoint inhibitors and tumor-infiltrating lymphocyte (TIL) therapies, has demonstrated encouraging outcomes in effectively combating cancer cells. These therapeutic agents demonstrate superior effectiveness and a more tolerable side-effect profile, improving the quality of life for patients receiving treatment. The future of melanoma treatment may involve a multimodal approach consisting of a combination of surgery, targeted therapy, and immunotherapy adapted to each patient's profile. This approach may improve survival rates and health outcomes.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"47 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141785483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systemic Management of Advanced Adrenocortical Carcinoma 晚期肾上腺皮质癌的全身治疗

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2024-07-27 DOI: 10.1007/s11864-024-01249-6

Jeffery S. Russell

{"title":"Systemic Management of Advanced Adrenocortical Carcinoma","authors":"Jeffery S. Russell","doi":"10.1007/s11864-024-01249-6","DOIUrl":"https://doi.org/10.1007/s11864-024-01249-6","url":null,"abstract":"Adrenocortical cancer (ACC) is a rare and aggressive disease. Surgery has traditionally been the primary treatment for locally advanced disease with ongoing controversy around the optimal neoadjuvant and adjuvant treatment options. Unfortunately, local recurrence and the eventual development of metastatic disease is common and five-year survival rates are poor. While many trials have evaluated novel systemic agents to treat advanced adrenocortical cancer, only a few drugs have demonstrated any response at all. To date, only one drug, mitotane, is approved in the US for ACC and no regimen has clearly shown an increase in overall survival. In advanced metastatic or unresectable disease, data supports the first line regimen of EDP chemotherapy + mitotane as the primary treatment modality. In the second line, while data is limited, we would recommend consideration of immunotherapy using a PD(L)1 agent combined with a TKI/VEGF inhibitor or combination immunotherapy with PD1/CTLA-4 drugs. In all cases, we always prefer a clinical trial as available. This article reviews data from multiple studies evaluating novel systemic agents against ACC and discusses current systemic therapy combinations and ongoing clinical trials.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"76 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141776329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Small Cell Lung Cancer—An Update on Chemotherapy Resistance 小细胞肺癌--化疗耐药性的最新进展

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2024-07-27 DOI: 10.1007/s11864-024-01245-w

Qian Ying, Ruiyun Fan, Yili Shen, Boyi Chen, Jianhui Zhang, Qiuhui Li, Xuefei Shi

引用次数: 0

Precision Treatment of Anthracycline-Induced Cardiotoxicity: An Updated Review 蒽环类药物诱发心脏毒性的精准治疗：最新综述

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2024-07-27 DOI: 10.1007/s11864-024-01238-9

Ziyu Kuang, Yuansha Ge, Luchang Cao, Xinmiao Wang, Kexin Liu, Jiaxi Wang, Xiaojuan Zhu, Min Wu, Jie Li

{"title":"Precision Treatment of Anthracycline-Induced Cardiotoxicity: An Updated Review","authors":"Ziyu Kuang, Yuansha Ge, Luchang Cao, Xinmiao Wang, Kexin Liu, Jiaxi Wang, Xiaojuan Zhu, Min Wu, Jie Li","doi":"10.1007/s11864-024-01238-9","DOIUrl":"https://doi.org/10.1007/s11864-024-01238-9","url":null,"abstract":"Anthracycline (ANT)-induced cardiotoxicity (AIC) is a particularly prominent form of cancer therapy-related cardiovascular toxicity leading to the limitations of ANTs in clinical practice. Even though AIC has drawn particular attention, the best way to treat it is remaining unclear. Updates to AIC therapy have been made possible by recent developments in research on the underlying processes of AIC. We review the current molecular pathways leading to AIC: 1) oxidative stress (OS) including enzymatic-induced and other mechanisms; 2) topoisomerase; 3) inflammatory response; 4) cardiac progenitor cell damage; 5) epigenetic changes; 6) renin-angiotensin-aldosterone system (RAAS) dysregulation. And we systematically discuss current prevention and treatment strategies and novel pathogenesis-based therapies for AIC: 1) dose reduction and change; 2) altering drug delivery methods; 3) antioxidants, dexrezosen, statina, RAAS inhibitors, and hypoglycemic drugs; 4) miRNA, natural phytochemicals, mesenchymal stem cells, and cardiac progenitor cells. We also offer a fresh perspective on the management of AIC by outlining the current dilemmas and challenges associated with its prevention and treatment.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"17 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141776328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current Treatment Options: Uterine Sarcoma. 当前的治疗方案：子宫肉瘤。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-07-01 Epub Date: 2024-05-31 DOI: 10.1007/s11864-024-01214-3

Dana Lewis, Angela Liang, Terri Mason, James Stuart Ferriss

{"title":"Current Treatment Options: Uterine Sarcoma.","authors":"Dana Lewis, Angela Liang, Terri Mason, James Stuart Ferriss","doi":"10.1007/s11864-024-01214-3","DOIUrl":"10.1007/s11864-024-01214-3","url":null,"abstract":"Opinion statement: The cornerstone of treatment for uterine sarcoma, regardless of histologic type, remains en bloc surgical resection with total hysterectomy. In the case of incidental diagnosis during another procedure, such as myomectomy, where a hysterectomy was not performed initially, completion hysterectomy or cervical remnant removal is recommended. The completion of additional surgical procedures, including bilateral salpingo-oophorectomy and lymphadenectomy, remains nuanced. Bilateral salpingo-oophorectomy remains controversial in the setting of most subtypes of uterine sarcoma, except in the case of hormone-receptor positivity, such as in low grade endometrial stromal sarcoma, where it is indicated as part of definitive surgical treatment. In the absence of apparent nodal involvement, we do not recommend performing universal lymphadenectomy for patients with sarcoma. We recommend systemic therapy for patients with extra-uterine or advanced stage disease, high-grade histology, and recurrence. The most active chemotherapy regimens for advanced, high-grade disease remain doxorubicin or gemcitabine and docetaxol combination therapy. A notable exception is low grade endometrial stromal sarcoma, where we recommend anti-hormonal therapy in the front-line setting. Radiation therapy is reserved for selected cases where it can aid in palliating symptoms.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"829-853"},"PeriodicalIF":3.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141180768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0